Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Non-Current Liabilities (2022 - 2025)

Heron Therapeutics (HRTX) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $236.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 11.06% year-over-year to $236.7 million, compared with a TTM value of $236.7 million through Dec 2025, down 11.06%, and an annual FY2025 reading of $236.7 million, down 11.06% over the prior year.
  • Total Non-Current Liabilities was $236.7 million for Q4 2025 at Heron Therapeutics, up from $229.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $266.2 million in Q4 2024 and bottomed at $229.4 million in Q3 2025.
  • Average Total Non-Current Liabilities over 4 years is $250.6 million, with a median of $253.6 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities rose 8.34% in 2024, then dropped 11.96% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $237.1 million in 2022, then increased by 8.05% to $256.2 million in 2023, then grew by 3.88% to $266.2 million in 2024, then fell by 11.06% to $236.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for HRTX at $236.7 million in Q4 2025, $229.4 million in Q3 2025, and $258.6 million in Q2 2025.